D2-40/podoplanin expression in cancer stroma by immunohistochemical staining is associated with poor prognosis in bladder cancer patients after radical cystectomy

•Podoplanin expression was found in high-risk bladder cancer stroma for the first time.•Cells in cancer stroma expressing podoplanin are morphologically fibroblast.•Podoplanin expression might be associated with poor prognosis after cystectomy. We assessed whether D2-40/podoplanin (PDPN) could be us...

Full description

Saved in:
Bibliographic Details
Published in:Urologic oncology 2020-10, Vol.38 (10), p.797.e7-797.e13
Main Authors: Okajima, Eijiro, Tomizawa, Mitsuru, Shimada, Keiji, Negishi, Takahito, Nishiyama, Naotaka, Kitamura, Hiroshi
Format: Article
Language:English
Subjects:
Bladder cancer
Chemotherapy
Podoplanin
Prognosis
Radical cystectomy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•Podoplanin expression was found in high-risk bladder cancer stroma for the first time.•Cells in cancer stroma expressing podoplanin are morphologically fibroblast.•Podoplanin expression might be associated with poor prognosis after cystectomy. We assessed whether D2-40/podoplanin (PDPN) could be used to identify bladder cancer patients with a higher probability of benefiting from cisplatin-based combination chemotherapy. We investigated PDPN expression by immunohistochemical analysis of cystectomy specimens from 96 bladder cancer patients who had undergone radical cystectomy without neoadjuvant or adjuvant cisplatin-based combination chemotherapy until recurrence. We classified the cases into 2 groups according to the achievement of 2-year recurrence-free survival (RFS) and evaluated whether PDPN expression was associated with patient prognosis. We also classified the 96 cases into 3 groups according to the possible need for perioperative chemotherapy based on the response to chemotherapy after recurrence as “unnecessary” (achieving 2-year RFS), “responder” (recurring within 2 years and responding to chemotherapy after recurrence), and “non-responder” (not responding chemotherapy following recurrence) and compared PDPN expression between these groups. Among 13 cases diagnosed with clinically
ISSN:1078-1439
1873-2496
DOI:10.1016/j.urolonc.2020.05.020